Drugs / DAOI-B
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01600469 | Jan 2012 → May 2013 | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | Chang Gung Memorial Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DAOI-B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01600469 ↗ |
| Action | Activate | “NMDA enhancer: DAOI-B group (starting dose: 250-500 mg/d)” NCT01600469 ↗ |
| Route | Oral | “250-1500 mg/day, oral, for 24 weeks” NCT01600469 ↗ |